Phathom names new CEO, executives

Updated 12/2/2019 12:25 PM

BUFFALO GROVE -- Phathom Pharmaceuticals announced Terrie Curran will become the company's CEO, one of many executive appointments at the late clinical-stage biopharmaceutical company.

In addition to Curran, founding CEO David Socks will become interim Chief Financial Officer and remain a member of the board of directors. Also joining Phathom are Eckhard Leifke, M.D., as Chief Medical Officer; Joseph Hand, J.D., as Chief Administrative Officer; and Larry Miller, J.D., as General Counsel.


Phathom also announced today that Asit Parikh, MD, Ph.D. has replaced Chris Slavinsky on the Company's board of directors.

Curran, who was previously president of the Global Inflammation and Immunology Franchise at Celgene since 2017, has more than 20 years of experience in the biopharmaceutical industry. She joined Celgene in 2013 as the U.S. Commercial Head of the I & I Franchise and built the capabilities and recruited the teams that executed the successful launch of Otezla, which was sold to Amgen in November 2019 for $13.4 billion. Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Women's Health at Merck & Co. She currently serves on the board of Myovant Sciences and previously served on the board of H. Lundbeck A/S.

Curran holds graduate and bachelor's degrees from the University of Technology, Sydney.

Article Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.